457 related articles for article (PubMed ID: 25595327)
1. Expert recommendations on treating psoriasis in special circumstances.
Carrascosa JM; Belinchón I; de-la-Cueva P; Izu R; Luelmo J; Ruiz-Villaverde R
Actas Dermosifiliogr; 2015 May; 106(4):292-309. PubMed ID: 25595327
[TBL] [Abstract][Full Text] [Related]
2. Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II).
Carrascosa JM; Galán M; de Lucas R; Pérez-Ferriols A; Ribera M; Yanguas I
Actas Dermosifiliogr; 2016 Nov; 107(9):712-729. PubMed ID: 27344068
[TBL] [Abstract][Full Text] [Related]
3. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
[TBL] [Abstract][Full Text] [Related]
4. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara Pinton P; Chimenti S; Martini P; Peserico A; Puglisi Guerra A; Vena GA;
J Dermatolog Treat; 2015 Apr; 26(2):128-33. PubMed ID: 24708158
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
6. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in the treatment of psoriatic arthritis.
Puig L; López-Ferrer A; Laiz A
Actas Dermosifiliogr; 2015 May; 106(4):252-9. PubMed ID: 25455504
[TBL] [Abstract][Full Text] [Related]
8. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper.
Yeung J; Gooderham MJ; Grewal P; Hong CH; Lansang P; Papp KA; Poulin Y; Turchin I; Vender R
J Cutan Med Surg; 2020; 24(1_suppl):3S-14S. PubMed ID: 32500730
[TBL] [Abstract][Full Text] [Related]
9. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
10. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
11. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis in pregnancy: a review (II).
Ruiz V; Manubens E; Puig L
Actas Dermosifiliogr; 2014 Nov; 105(9):813-21. PubMed ID: 24314892
[TBL] [Abstract][Full Text] [Related]
14. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
15. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
17. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
De Simone C; Amerio P; Amoruso G; Bardazzi F; Campanati A; Conti A; Gisondi P; Gualdi G; Guarneri C; Leoni L; Loconsole F; Mazzotta A; Musumeci ML; Piaserico S; Potenza C; Prestinari F
Expert Opin Biol Ther; 2013 Dec; 13(12):1673-82. PubMed ID: 24107126
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.
Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211
[TBL] [Abstract][Full Text] [Related]
20. [Psoriatic arthritis: what the dermatologist needs to know, Part 2].
López-Ferrer A; Torrente-Segarra V; Puig L
Actas Dermosifiliogr; 2010 Nov; 101(9):742-8. PubMed ID: 21034704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
